Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | BRD4 | O60885 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SGK1 | O00141 | 13/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4845088 | 1.00 | SMN1; SMN2 (0.41) | SMN1; SMN2BRD4LMNAHPGDSGK1 | |
| SCHEMBL4844095 | 0.91 | LMNA (0.45) | SMN1; SMN2BRD4LMNAHPGDSGK1 | |
| SCHEMBL4844083 | 0.91 | LMNA (0.45) | SMN1; SMN2BRD4LMNAHPGDSGK1 | |
| SCHEMBL4841681 | 0.87 | LMNA (0.39) | SMN1; SMN2LMNAHPGDNFE2L2 | |
| SCHEMBL4841676 | 0.87 | LMNA (0.39) | SMN1; SMN2LMNAHPGDNFE2L2 | |
| SCHEMBL4846544 | 0.87 | SMN1; SMN2 (0.54) | SMN1; SMN2LMNAHPGD | |
| SCHEMBL4846537 | 0.87 | SMN1; SMN2 (0.54) | SMN1; SMN2LMNAHPGD | |
| SCHEMBL4835762 | 0.85 | LMNA (0.41) | SMN1; SMN2LMNAHPGDNFE2L2 | |
| SCHEMBL4835755 | 0.85 | LMNA (0.41) | SMN1; SMN2LMNAHPGDNFE2L2 | |
| SCHEMBL4834736 | 0.85 | SMN1; SMN2 (0.39) | SMN1; SMN2LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7378428-B2 | Nitrogen-containing bicyclic compounds and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-05-27 | — | — | US | disclosed |
| US-20050222138-A1 | Nitrogen-containing bicyclic compounds and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222138-A1 | Nitrogen-containing bicyclic compounds and drugs containing the same as the active ingredient | PARK7, MMP8, CDK7 | SMN1; SMN2 144/4885BRD4 1577/4885LMNA 3014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.